Clonal	Clonal	JJ	B-NP	O		0	6
strains	strain	NNS	I-NP	O		7	14
of	of	IN	B-PP	O		15	17
Pseudomonas aeruginosa	Pseudomonas_aeruginosa	NN	B-NP	O		18	40
in	in	IN	B-PP	O		41	43
paediatric	paediatric	JJ	B-NP	O		44	54
and	and	CC	I-NP	O		55	58
adult	adult	JJ	I-NP	O		59	64
cystic	cystic	JJ	I-NP	O		65	71
fibrosis	fibrosis	NN	I-NP	O		72	80
units	unit	NNS	I-NP	O		81	86
.	.	.	O	O		86	87

Despite	Despite	IN	B-PP	O		88	95
recent	recent	JJ	B-NP	O		96	102
reports	report	NNS	I-NP	O		103	110
of	of	IN	B-PP	O		111	113
clonal	clonal	JJ	B-NP	O		114	120
strains	strain	NNS	I-NP	O		121	128
of	of	IN	B-PP	O		129	131
Pseudomonas aeruginosa	Pseudomonas_aeruginosa	NN	B-NP	O		132	154
in	in	IN	B-PP	O		155	157
cystic	cystic	JJ	B-NP	B-protein		158	164
fibrosis	fibrosis	NN	I-NP	I-protein		165	173
(	(	(	O	I-protein		174	175
CF	CF	NN	B-NP	I-protein		175	177
)	)	)	O	I-protein		177	178
units	unit	NNS	B-NP	I-protein		179	184
,	,	,	O	O		184	185
the	the	DT	B-NP	O		186	189
need	need	NN	I-NP	O		190	194
for	for	IN	B-PP	O		195	198
routine	routine	JJ	B-NP	O		199	206
microbiological	microbiological	JJ	I-NP	O		207	222
surveillance	surveillance	NN	I-NP	O		223	235
remains	remain	VBZ	B-VP	O		236	243
contentious	contentious	JJ	B-ADJP	O		244	255
.	.	.	O	O		255	256

Sputum	Sputum	NNP	B-NP	O		257	263
was	be	VBD	B-VP	O		264	267
collected	collect	VBN	I-VP	O		268	277
prospectively	prospectively	RB	B-ADVP	O		278	291
from	from	IN	B-PP	O		292	296
productive	productive	JJ	B-NP	O		297	307
patients	patient	NNS	I-NP	O		308	316
attending	attend	VBG	B-VP	O		317	326
the	the	DT	B-NP	O		327	330
regional	regional	JJ	I-NP	O		331	339
paediatric	paediatric	JJ	I-NP	O		340	350
and	and	CC	I-NP	O		351	354
adult	adult	JJ	I-NP	O		355	360
CF	CF	NN	I-NP	O		361	363
units	unit	NNS	I-NP	O		364	369
in	in	IN	B-PP	O		370	372
Brisbane	Brisbane	NNP	B-NP	O		373	381
,	,	,	O	O		381	382
Australia	Australia	NNP	B-NP	O		383	392
.	.	.	O	O		392	393

All	All	DT	B-NP	O		394	397
P. aeruginosa	P._aeruginosa	NNP	I-NP	O		398	411
isolates	isolate	NNS	I-NP	O		412	420
were	be	VBD	B-VP	O		421	425
typed	type	VBN	I-VP	O		426	431
using	use	VBG	B-VP	O		432	437
pulsed	pulsed	JJ	B-NP	O		438	444
-	-	HYPH	I-NP	O		444	445
field	field	NN	I-NP	O		445	450
gel	gel	NN	I-NP	O		451	454
electrophoresis	electrophoresis	NN	I-NP	O		455	470
.	.	.	O	O		470	471

Spirometry	Spirometry	NN	B-NP	O		472	482
,	,	,	O	O		482	483
anthropometrics	anthropometric	NNS	B-NP	O		484	499
,	,	,	O	O		499	500
hospitalisations	hospitalisation	NNS	B-NP	O		501	517
and	and	CC	O	O		518	521
antibiotic	antibiotic	JJ	B-NP	O		522	532
sensitivity	sensitivity	NN	I-NP	O		533	544
data	datum	NNS	I-NP	O		545	549
were	be	VBD	B-VP	O		550	554
recorded	record	VBN	I-VP	O		555	563
.	.	.	O	O		563	564

The	The	DT	B-NP	O		565	568
first	first	JJ	I-NP	O		569	574
100	100	CD	I-NP	O		575	578
sputum	sputum	NN	I-NP	O		579	585
samples	sample	NNS	I-NP	O		586	593
(	(	(	O	O		594	595
first	first	JJ	B-NP	O		595	600
50	50	CD	I-NP	O		601	603
patients	patient	NNS	I-NP	O		604	612
at	at	IN	B-PP	O		613	615
each	each	DT	B-NP	O		616	620
clinic	clinic	NN	I-NP	O		621	627
)	)	)	O	O		627	628
harboured	harbour	VBD	B-VP	O		629	638
163	163	CD	B-NP	O		639	642
isolates	isolate	NNS	I-NP	O		643	651
of	of	IN	B-PP	O		652	654
P. aeruginosa	P._aeruginosa	NNP	B-NP	O		655	668
.	.	.	O	O		668	669

A	A	DT	B-NP	O		670	671
total	total	NN	I-NP	O		672	677
of	of	IN	B-PP	O		678	680
39	39	CD	B-NP	O		681	683
patients	patient	NNS	I-NP	O		684	692
shared	share	VBD	B-VP	O		693	699
a	a	DT	B-NP	O		700	701
common	common	JJ	I-NP	O		702	708
strain	strain	NN	I-NP	O		709	715
(	(	(	O	O		716	717
pulsotype	pulsotype	NN	B-NP	O		717	726
2	2	CD	I-NP	O		727	728
)	)	)	O	O		728	729
,	,	,	O	O		729	730
20	20	CD	B-NP	O		731	733
patients	patient	NNS	I-NP	O		734	742
shared	share	VBD	B-VP	O		743	749
a	a	DT	B-NP	O		750	751
strain	strain	NN	I-NP	O		752	758
with	with	IN	B-PP	O		759	763
at	at	IN	B-NP	O		764	766
least	least	JJS	I-NP	O		767	772
one	one	CD	I-NP	O		773	776
other	other	JJ	I-NP	O		777	782
patient	patient	NN	I-NP	O		783	790
and	and	CC	O	O		791	794
41	41	CD	B-NP	O		795	797
patients	patient	NNS	I-NP	O		798	806
harboured	harbour	VBD	B-VP	O		807	816
unique	unique	JJ	B-NP	O		817	823
strains	strain	NNS	I-NP	O		824	831
.	.	.	O	O		831	832

Eight	Eight	CD	B-NP	O		833	838
patients	patient	NNS	I-NP	O		839	847
shared	share	VBD	B-VP	O		848	854
a	a	DT	B-NP	O		855	856
strain	strain	NN	I-NP	O		857	863
identical	identical	JJ	B-ADJP	O		864	873
to	to	TO	B-PP	O		874	876
a	a	DT	B-NP	O		877	878
previously	previously	RB	I-NP	O		879	889
reported	report	VBN	I-NP	O		890	898
Australian	Australian	JJ	I-NP	O		899	909
transmissible	transmissible	JJ	I-NP	O		910	923
strain	strain	NN	I-NP	O		924	930
(	(	(	O	O		931	932
pulsotype	pulsotype	NN	B-NP	O		932	941
1	1	CD	I-NP	O		942	943
)	)	)	O	O		943	944
.	.	.	O	O		944	945

Compared	Compare	VBN	B-PP	O		946	954
with	with	IN	B-PP	O		955	959
the	the	DT	B-NP	O		960	963
unique	unique	JJ	I-NP	O		964	970
strain	strain	NN	I-NP	O		971	977
group	group	NN	I-NP	O		978	983
,	,	,	O	O		983	984
patients	patient	NNS	B-NP	O		985	993
harbouring	harbour	VBG	B-VP	O		994	1004
pulsotype	pulsotype	NN	B-NP	O		1005	1014
2	2	CD	I-NP	O		1015	1016
were	be	VBD	B-VP	O		1017	1021
younger	young	JJR	B-ADJP	O		1022	1029
and	and	CC	O	O		1030	1033
had	have	VBD	B-VP	O		1034	1037
poorer	poor	JJR	B-NP	O		1038	1044
lung	lung	NN	I-NP	O		1045	1049
function	function	NN	I-NP	O		1050	1058
.	.	.	O	O		1058	1059

Treatment	Treatment	NN	B-NP	O		1060	1069
requirements	requirement	NNS	I-NP	O		1070	1082
were	be	VBD	B-VP	O		1083	1087
similar	similar	JJ	B-ADJP	O		1088	1095
in	in	IN	B-PP	O		1096	1098
these	these	DT	B-NP	O		1099	1104
two	two	CD	I-NP	O		1105	1108
groups	group	NNS	I-NP	O		1109	1115
,	,	,	O	O		1115	1116
as	as	IN	B-SBAR	O		1117	1119
were	be	VBD	B-VP	O		1120	1124
the	the	DT	B-NP	O		1125	1128
rates	rate	NNS	I-NP	O		1129	1134
of	of	IN	B-PP	O		1135	1137
multiresistance	multiresistance	NN	B-NP	O		1138	1153
.	.	.	O	O		1153	1154

In	In	IN	B-PP	O		1155	1157
conclusion	conclusion	NN	B-NP	O		1158	1168
,	,	,	O	O		1168	1169
59%	59%	CD	B-NP	O		1170	1173
of	of	IN	B-PP	O		1174	1176
patients	patient	NNS	B-NP	O		1177	1185
harboured	harbour	VBD	B-VP	O		1186	1195
a	a	DT	B-NP	O		1196	1197
clonal	clonal	JJ	I-NP	O		1198	1204
strain	strain	NN	I-NP	O		1205	1211
,	,	,	O	O		1211	1212
supporting	support	VBG	B-VP	O		1213	1223
the	the	DT	B-NP	O		1224	1227
need	need	NN	I-NP	O		1228	1232
for	for	IN	B-PP	O		1233	1236
routine	routine	JJ	B-NP	O		1237	1244
microbiological	microbiological	JJ	I-NP	O		1245	1260
surveillance	surveillance	NN	I-NP	O		1261	1273
.	.	.	O	O		1273	1274

In	In	IN	B-PP	O		1275	1277
contrast	contrast	NN	B-NP	O		1278	1286
to	to	TO	B-PP	O		1287	1289
previously	previously	RB	B-NP	O		1290	1300
described	describe	VBN	I-NP	O		1301	1310
clonal	clonal	JJ	I-NP	O		1311	1317
strains	strain	NNS	I-NP	O		1318	1325
,	,	,	O	O		1325	1326
the	the	DT	B-NP	O		1327	1330
dominant	dominant	JJ	I-NP	O		1331	1339
pulsotype	pulsotype	NN	I-NP	O		1340	1349
was	be	VBD	B-VP	O		1350	1353
indistinguishable	indistinguishable	JJ	B-ADJP	O		1354	1371
from	from	IN	B-PP	O		1372	1376
nonclonal	nonclonal	JJ	B-NP	O		1377	1386
strains	strain	NNS	I-NP	O		1387	1394
with	with	IN	B-PP	O		1395	1399
respect	respect	NN	B-NP	O		1400	1407
to	to	TO	B-PP	O		1408	1410
both	both	CC	O	O		1411	1415
colonial	colonial	NN	B-NP	O		1416	1424
morphology	morphology	NN	I-NP	O		1425	1435
and	and	CC	O	O		1436	1439
multiresistance	multiresistance	NN	B-NP	O		1440	1455
.	.	.	O	O		1455	1456

The	The	DT	B-NP	O		1457	1460
clinical	clinical	JJ	I-NP	O		1461	1469
significance	significance	NN	I-NP	O		1470	1482
of	of	IN	B-PP	O		1483	1485
clonal	clonal	JJ	B-NP	O		1486	1492
strains	strain	NNS	I-NP	O		1493	1500
remains	remain	VBZ	B-VP	O		1501	1508
uncertain	uncertain	JJ	B-ADJP	O		1509	1518
and	and	CC	O	O		1519	1522
requires	require	VBZ	B-VP	O		1523	1531
longitudinal	longitudinal	JJ	B-NP	O		1532	1544
study	study	NN	I-NP	O		1545	1550
.	.	.	O	O		1550	1551

